StockpollyBeta
Get App
Popularity #1,192
SRRK · NASDAQ · Biotechnology

Scholar Rock (SRRK)

Develops anti-myostatin antibodies for spinal muscular atrophy and other neuromuscular diseases.

$51.19
After hours−0.01 (−0.02%)
At close$51.20(+6.31%)

  1. Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP

    Defense World

  2. Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

    Seeking Alpha

  3. Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

    Seeking Alpha

  4. Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

    Benzinga

  5. Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

    Reuters

  6. Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

    Benzinga

  7. Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

    Business Wire

  8. US FDA approves Scholar Rock's muscle weakness drug

    Reuters

  9. Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

    Seeking AlphaEarnings

  10. 9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.

    Defense WorldOwnership

  11. Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

    MarketBeatClinical

  12. Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

    Business Wire

  13. Scholar Rock Q2 Earnings Call Highlights

    MarketBeat

  14. Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

    Seeking Alpha

  15. Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

    GuruFocus

  16. Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

    Business Wire

  17. Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

    GuruFocus

  18. Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

    PRNewsWire

  19. Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

    GlobeNewsWire

  20. Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026

    Reuters